Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aslan Pharmaceuticals Ltd ADR (NQ: ASLN )

0.6300 -0.0602 (-8.72%)
Streaming Delayed Price Updated: 3:59 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 216,574
Open 0.6854
Bid (Size) 0.6300 (1)
Ask (Size) 0.6531 (10)
Prev. Close 0.6902
Today's Range 0.6300 - 0.7110
52wk Range 0.6300 - 4.575
Shares Outstanding 402,116,835
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ASLAN Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire

Performance

YTD
-71.05%
-71.05%
1 Month
-42.73%
-42.73%
3 Month
-70.83%
-70.83%
6 Month
-84.21%
-84.21%
1 Year
-76.34%
-76.34%

More News

Read More
ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
4 Analysts Have This to Say About ASLAN Pharma
Via Benzinga
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
3 Stocks to Sell Ahead of the Coming VIX Spike
Via InvestorPlace
Topics Stocks
Exposures US Equities
ASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology Congress
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why iMedia Brands Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Dow Drops 75 Points; US Economy Adds 209,000 Jobs In June
Via Benzinga
Nasdaq Drops Over 100 Points; Genius Sports Shares Spike Higher
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Moves Lower; ISM Services PMI Surges In June
Via Benzinga
Why Caribou Biosciences Shares Are Trading Higher By Around 58%? Here Are Other Stocks Moving In Thursday's Session
Via Benzinga
Dow Tumbles Over 300 Points; US Jobless Claims Increase More Than Projected
Via Benzinga
What's Going On With ASLAN Pharmaceuticals Stock Today?
Via Benzinga
Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in Atopic Dermatitis
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic Dermatitis
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimab’s Unique Mechanism of Action in the Treatment of Atopic Dermatitis
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Inks Licensing Deal With Zenyaku Kogyo To Commercialize Eblasakimab In Japan
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.